Hawaii Macula and Retina Institute Timeline of Significant Events

Timeline of Important Events in Retina Research

2017

2016

  • Dr. Gregg Kokame presents OCT Angiography for Polypoidal Choroidal Vasculopathy at the 39th Annual Macula Society Meeting in February 2016
  • HMRI’s Third ARGUS II surgery was a featured story on Japan’s FUJI TV channel on March 3, 2016
  • Regeneron ONYX and RUBY: REGN910-3 for Wet AMD (9 month study Begins)
  • Ohr MAKO: Topical Squalamine for Wet AMD (9 month study begins)
  • Dr. Raymond Wee presents at the Ocular Imaging Conference / Western Association for Vitreoretinal Education (OIC/WAVE) in Colorado in June 2016
  • Dr. Gregg Kokame presents over the Bionic Eye in Taiwan for the Retina International World Congress in July 2016
  • Dr. Raymond Wee presents PCV research from HMRI at American Society of Retinal Specialists in August 2016 in San Francisco
  • Dr. James Lai introduces results of HMRI’s Pearl II study results at the 49th Annual Retina Society Meeting in San Diego.
  • HMRI doctor, Gregg Kokame invited to teach the PCV course during Retina Subspecialty Day in Chicago, October 2016
  • Dr. Gregg Kokame traveled to Tokyo to present at the Japanese Retina and Vitreous Society in December of 2016

2015

2014

  • HMRI Approved as Site for Second Sight ARGUS II Retinal Prosthesis Post-Approval Study
  • Investigator Sponsored Trial (EPIC): Eylea® for Polypoidal Choroidal Vasculopathy (PCV) (Updated to 2 Year Study)
  • Allergan PALM: DARPin for Diabetic Macular Edema (7 month Study Begins)
  • Thrombogenics ORBIT:  Jetrea Safety Assessment for Vitreomacular Adhesion (1 Year Study Begins)
  • Genentech CHROMA:  Lampalizumab for Dry AMD with Geographic Atrophy (2 Year Study Begins)

2013

  • Acucela: Visual Cycle Modulators for Dry AMD (2 Year Study Begins)
  • Investigator Sponsored Trial (EPIC): Eylea® for Polypoidal Choroidal Vasculopathy (PCV) (1 Year Study Begins)
  • Lpath: iSONEP +/- Avastin, Eylea or Lucentis for Exudative Macular Degeneration (1 Year Study Begins)

2012

  • FDA Approved Lucentis™ 0.3mg for the Treatment of Diabetic Macular Edema
  • FDA Approves Eylea® for the Treatment of Exudative Macular Degeneration
  • Allergan: REACH: DARPin for Wet-AMD (1 Year Study) Begins
  • JDRF (Juvenile Diabetes Research Foundation): IDEAL: ico-007
  • Barnes Retina: CRAVE: Lucentis vs Avastin for Retinal Vein Occlusion (RVO) (1 Year Study) Begins

2011

  • Regeneron: VISTA: Eylea™ +/- Laser Photocoagulation Study for Diabetic Macular Edema (3-Year Study) Begins

2010

  • Regeneron: VIEW1 Extension Study: Eylea® for Wet-AMD (3 Year Study) Begins
  • Acucela: ENVISION CLARITY: Visual Cycle Modulators (VCM) for Dry AMD (3-Month Study) Begins
  • Investigator Sponsored Trial: PEARL2: 2.0mg Lucentis™ for Polypoidal Choroidal Vasculopathy (PCV) (2-year Study) Begins

2009

  • Genentech: HARBOR: 2.0mg (High-Dose) Lucentis™ for Wet-AMD (2-Year Study) Begins
  • Macusight: DIAMOND: rapamycin for Diabetic Macular Edema (DME) (3-Year Study) Begins

2008

  • Regeneron: VIEW1: Eylea® for Wet-AMD (2-Year) Study Begins
  • Allergan: POSURDEX: Ozurdex +/- Laser Photocoagulation for Diabetic Macular Edema (DME) Study (15 Month Study Begins)
  • Pfizer: QUARK: siRNA for Wet-AMD (2-Year Study) Begins
  • COBALT: siRNA for Wet-AMD (2-Year Study) Begins

2007

  • Genentech: RISE: Lucentis™ for Diabetic Macular Edema (DME) (3-Year Study) Begins
  • Novartis: DENALI: Visudyne™ +/- Lucentis™ (2-Year Study) Begins
  • Asian AMD Genetic Study Begins

2006

  • FDA Approves Lucentis™ for the Treatment of Exudative Macular Degeneration
  • Investigator Sponsored Trial: PEARL: Lucentis™ for Polypoidal Choroidal Vasculopathy (PCV) Study (1 Year Study)

2005

  • Eyetech: EOP1012: Macugen® for Wet-AMD (2-Year Study) Begins
  • Genentech: HORIZON: Extension Study for Lucentis for AMD (5-Year Study) Begins
  • DRCR.net: Protocol D: Vitrectory for Diabetic Macular Edema (DME) (3-Year Study) Begins
  • Eyetech: EOP1013: Macugen® for Diabetic Macular Edema (3-Year Study) Begins
  • Genentech: SAILOR: Lucentis™ for Wet-AMD (1 Year Study) Begins

2004

  • DRCR.net: Protocol B: Intravitreal Triamcinolone vs Laser Photocoagulation for Diabetic Macular Edema (DME) (3-Year Study) Begins
  • LuEster Mertz/Novartis: VisTA: Triamcinolone +/- Visudyne PDT (2-Year Study) Begins

2003

  • Genentech: MARINA Study: Lucentis for Wet-AMD (2-Year Study) Begins
  • DRCR.net: Protocol A: Laser Photocoagulation for Diabetic Macular Edema (DME) (3-Year Study) Begins

2002

  • FDA Approves Visudyne™ for the Treatment of Exudative Macular Degeneration
  • Genentech: FOCUS Study: Lucentis +/- Visudyne™ Photodynamic Therapy for Wet-AMD (2-year Study) Begins

2001

  • Eli Lilly PKC Study: Oral Medicaion for Diabetic Retinopathy (4-year Study) Begins

1993 – Research at HMRI begins under the direction of Gregg T. Kokame, MD